---
title: "NanoXplore reported Q2-2026 results: $27.58M revenues (17% decrease), $3.84M loss, $224k EBITDA. Strategic decision to not pursue $100M initiative."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275517685.md"
description: "NanoXplore Inc. reported Q2-2026 results with revenues of $27.58M, a 17% decrease year-over-year, and a loss of $3.84M. Adjusted EBITDA was $224k, down from $1.1M last year. The company has total liquidity of $40.14M and long-term debt of $13.92M. They opted not to pursue a $100M initiative for active anode materials. Despite challenges, Q2 showed revenue growth and positive adjusted EBITDA due to stable customer volumes and new revenues. Non-IFRS measures like Adjusted EBITDA and gross margin provide additional insights for investors."
datetime: "2026-02-10T21:46:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275517685.md)
  - [en](https://longbridge.com/en/news/275517685.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275517685.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275517685.md) | [繁體中文](https://longbridge.com/zh-HK/news/275517685.md)


# NanoXplore reported Q2-2026 results: $27.58M revenues (17% decrease), $3.84M loss, $224k EBITDA. Strategic decision to not pursue $100M initiative.

NanoXplore Inc., a leading graphene company, reported their financial results for the periods ending December 31, 2025. In Q2-2026, they had total revenues of $27,580,290, a 17% decrease from the previous year. Adjusted gross margin was 21.5%, and they experienced a loss of $3,836,406, compared to a loss of $2,894,922 last year. Adjusted EBITDA was $224,355, down from $1,102,050 last year. They had total liquidity of $40,144,435, with cash and cash equivalents at $30,144,435. The long-term debt was $13,922,418, up by $9,609,494 compared to the previous period. They decided against pursuing a $100 million active anode material initiative. Despite a challenging Q1, Q2 showed revenue growth and positive adjusted EBITDA, thanks to stable customer volumes and new revenues. Their non-IFRS financial measures include 'Adjusted EBITDA' and 'Adjusted gross margin'. The company believes these measures provide additional insight for investors in assessing their performance. The full story is available on Benzinga.com.

### Related Stocks

- [Nano-X Imaging Ltd. (NNOX.US)](https://longbridge.com/en/quote/NNOX.US.md)
- [Nanophase Technologies Corporation (NANX.US)](https://longbridge.com/en/quote/NANX.US.md)

## Related News & Research

- [Kontafarma Warns of Wider Losses for 2025](https://longbridge.com/en/news/278827704.md)
- [King's Flair Warns of 2025 Loss](https://longbridge.com/en/news/278688984.md)
- [Data and analytics firm Health Catalyst's Q4 revenue fell](https://longbridge.com/en/news/278946410.md)
- [Inspired Entertainment Q4 revenue falls](https://longbridge.com/en/news/278543069.md)
- [Biote Q4 revenue slightly beats estimates](https://longbridge.com/en/news/278773697.md)